J3Z as a free ligand exists in 4 entries. Examples include: 6MNE 3HM1 5HS6

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC18 H22 O2
Molecular Weight270.37
Isomeric SMILESC[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O

Chemical Details

Formal Charge0
Atom Count42
Chiral Atom Count4
Chiral AtomsC10, C12, C2, C5
Bond Count45
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00655 Different stereochemistry
DescriptionEstrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
  • 3-Hydroxy-1,3,5(10)-estratrien-17-one
  • Estrona
  • Estrone
  • Estronum
  • follicular hormone
Brand Names
  • Estragyn Vaginal Cream
  • Oestrilin Cones Vaginaux
  • Oestrilin Creme Vaginale 1mg
  • Estrone
Affected OrganismHumans and other mammals
IndicationFor management of perimenopausal and postmenopausal symptoms.
PharmacologyEstrone, a synthetically prepared or naturally occurring steroidal estrogen obtained from pregnant equine urine, is the primary circulating estrogen after menopause. Estrone is naturally derived from the peripheral conversion of androstenedione by an aromatase enzyme found in adipose tissues and is converted to estradiol in peripheral tissues. The estrogenic potency of estrone is one third that of estradiol. Estropipate is piperazine-stabilized estrone sulfate. Estrone, and estropipate are used to treat abnormalities related to gonadotropin hormone dysfunction, vasomotor symptoms, atrophic vaginitis, and vulvar atrophy associated with menopause, and for the prevention of osteoporosis due to estrogen deficiency.
Mechanism of actionEstrogens enter the cells of responsive tissues (e.g. female organs, breasts, hypothalamus, pituitary) where they interact with estrogen receptors. Hormone-bound estrogen receptors dimerize, translocate to the nucleus of cells and bind to estrogen response elements (ERE) of genes. Binding to ERE alters the transcription rate of affected genes. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) release from the anterior pituitary.
Route of administrationVaginal
  • 17-Ketosteroids
  • Adrenal Cortex Hormones
  • BCRP/ABCG2 Inhibitors
  • Chemical Actions and Uses
  • Cytochrome P-450 CYP1A2 Substrates
  • G03CA07
  • G03CC04
  • 68:16.04
  • 92:02.00*
CAS number53-16-7

Drug Targets

NameSequence SearchPharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682